Skip to Main Content

Author Details

Joshua M Stuart
University of California at Santa Cruz
2000
105
49
PMIDPaper TitleJournal TitlePublished Year
36697832Author Correction: Analyses of non-coding somatic drivers in 2,658 cancer whole genomes.Nature2023
36697832Author Correction: Analyses of non-coding somatic drivers in 2,658 cancer whole genomes.Nature2023
35079083Dual RNA-Seq analysis of SARS-CoV-2 correlates specific human transcriptional response pathways directly to viral expression.Sci Rep2022
36109521Transcriptional profiling of matched patient biopsies clarifies molecular determinants of enzalutamide-induced lineage plasticity.Nat Commun2022
35079083Dual RNA-Seq analysis of SARS-CoV-2 correlates specific human transcriptional response pathways directly to viral expression.Sci Rep2022
36109521Transcriptional profiling of matched patient biopsies clarifies molecular determinants of enzalutamide-induced lineage plasticity.Nat Commun2022
32286548Clinical and genomic characterization of Low PSA Secretors: a unique subset of metastatic castration resistant prostate cancer.Prostate Cancer Prostatic Dis2021
32286548Clinical and genomic characterization of Low PSA Secretors: a unique subset of metastatic castration resistant prostate cancer.Prostate Cancer Prostatic Dis2021
33861732Accurate cancer phenotype prediction with AKLIMATE, a stacked kernel learner integrating multimodal genomic data and pathway knowledge.PLoS Comput Biol2021
33626341Whole-genome characterization of lung adenocarcinomas lacking alterations in the RTK/RAS/RAF pathway.Cell Rep2021
34146471A community challenge to evaluate RNA-seq, fusion detection, and isoform quantification methods for cancer discovery.Cell Syst2021
34764310Towards inferring nanopore sequencing ionic currents from nucleotide chemical structures.Nat Commun2021
34584103VEGA is an interpretable generative model for inferring biological network activity in single-cell transcriptomics.Nat Commun2021
33626341Whole-genome characterization of lung adenocarcinomas lacking alterations in the RTK/RAS/RAF pathway.Cell Rep2021
33861732Accurate cancer phenotype prediction with AKLIMATE, a stacked kernel learner integrating multimodal genomic data and pathway knowledge.PLoS Comput Biol2021
34764310Towards inferring nanopore sequencing ionic currents from nucleotide chemical structures.Nat Commun2021
34584103VEGA is an interpretable generative model for inferring biological network activity in single-cell transcriptomics.Nat Commun2021
34146471A community challenge to evaluate RNA-seq, fusion detection, and isoform quantification methods for cancer discovery.Cell Syst2021
32424106Transcriptional profiling identifies an androgen receptor activity-low, stemness program associated with enzalutamide resistance.Proc Natl Acad Sci U S A2020
31797609Using Transcriptional Signatures to Find Cancer Drivers with LURE.Pac Symp Biocomput2020
32424106Transcriptional profiling identifies an androgen receptor activity-low, stemness program associated with enzalutamide resistance.Proc Natl Acad Sci U S A2020
32097025Exploring Integrative Analysis Using the BioMedical Evidence Graph.JCO Clin Cancer Inform2020
33490923Prioritizing transcriptional factors in gene regulatory networks with PageRank.iScience2020
32736587A risk-associated Active transcriptome phenotype expressed by histologically normal human breast tissue and linked to a pro-tumorigenic adipocyte population.Breast Cancer Res2020
32624423Down-regulation of ADRB2 expression is associated with small cell neuroendocrine prostate cancer and adverse clinical outcomes in castration-resistant prostate cancer.Urol Oncol2020
32727885Copy Number Loss of 17q22 Is Associated with Enzalutamide Resistance and Poor Prognosis in Metastatic Castration-Resistant Prostate Cancer.Clin Cancer Res2020
33490923Prioritizing transcriptional factors in gene regulatory networks with PageRank.iScience2020
32097025Exploring Integrative Analysis Using the BioMedical Evidence Graph.JCO Clin Cancer Inform2020
31797609Using Transcriptional Signatures to Find Cancer Drivers with LURE.Pac Symp Biocomput2020
32736587A risk-associated Active transcriptome phenotype expressed by histologically normal human breast tissue and linked to a pro-tumorigenic adipocyte population.Breast Cancer Res2020
32624423Down-regulation of ADRB2 expression is associated with small cell neuroendocrine prostate cancer and adverse clinical outcomes in castration-resistant prostate cancer.Urol Oncol2020
32727885Copy Number Loss of 17q22 Is Associated with Enzalutamide Resistance and Poor Prognosis in Metastatic Castration-Resistant Prostate Cancer.Clin Cancer Res2020
30557523Reply to A. Dalla Volta et al.J Clin Oncol2019
31653878Biological process activity transformation of single cell gene expression for cross-species alignment.Nat Commun2019
30557523Reply to A. Dalla Volta et al.J Clin Oncol2019
31506093Reproducible biomedical benchmarking in the cloud: lessons from crowd-sourced data challenges.Genome Biol2019
30864317PLATYPUS: A Multiple-View Learning Predictive Framework for Cancer Drug Sensitivity Prediction.Pac Symp Biocomput2019
30804427MEK-ERK signaling is a therapeutic target in metastatic castration resistant prostate cancer.Prostate Cancer Prostatic Dis2019
31653878Biological process activity transformation of single cell gene expression for cross-species alignment.Nat Commun2019
31506093Reproducible biomedical benchmarking in the cloud: lessons from crowd-sourced data challenges.Genome Biol2019
30864317PLATYPUS: A Multiple-View Learning Predictive Framework for Cancer Drug Sensitivity Prediction.Pac Symp Biocomput2019
30804427MEK-ERK signaling is a therapeutic target in metastatic castration resistant prostate cancer.Prostate Cancer Prostatic Dis2019
29625048Cell-of-Origin Patterns Dominate the Molecular Classification of 10,000 Tumors from 33 Types of Cancer.Cell2018
30400818Combining accurate tumor genome simulation with crowdsourcing to benchmark somatic structural variant detection.Genome Biol2018
30253747Valection: design optimization for validation and verification studies.BMC Bioinformatics2018
30340047Genomic Hallmarks and Structural Variation in Metastatic Prostate Cancer.Cell2018
30096302Comprehensive Characterization of Cancer Driver Genes and Mutations.Cell2018
29898407Integrated Molecular Characterization of Testicular Germ Cell Tumors.Cell Rep2018
30033370Genomic Hallmarks and Structural Variation in Metastatic Prostate Cancer.Cell2018
29985747Clinical and Genomic Characterization of Treatment-Emergent Small-Cell Neuroendocrine Prostate Cancer: A Multi-institutional Prospective Study.J Clin Oncol2018
  • 1 - 50 of 210

Recommended Authors

Perelman School of Medicine, University of Pennsylvania
Career Start Year 2018
Number of shared co-authors 1
University of Lausanne, Switzerland Swiss Cancer Center Leman
Career Start Year 2012
Number of shared co-authors 24
Broad Institute of Harvard and MIT
Career Start Year 2010
Number of shared co-authors 12
Benaroya Research Institute at Virginia Mason, Institute for Systems Biology, Sage Bionetworks, University of Illinois at Urbana-Champaign
Career Start Year 2008
Number of shared co-authors 49
Brigham Young University
Career Start Year 2008
Number of shared co-authors 19
T.J. Watson Research Center
Career Start Year 2008
Number of shared co-authors 27
University of Colorado Anschutz Medical Campus
Career Start Year 2006
Number of shared co-authors 36
Dana-Farber Cancer Institute
Career Start Year 2006
Number of shared co-authors 31
Center for Molecular Medicine, University Medical Center Utrecht
Career Start Year 2006
Number of shared co-authors 7
Prostate Cancer Research Center, Tampere University and Tays Cancer Center
Career Start Year 2006
Number of shared co-authors 43
Pacific Northwest National Laboratory (PNNL)
Career Start Year 2006
Number of shared co-authors 5
Karolinska Institutet
Career Start Year 2006
Number of shared co-authors 3
Baylor College of Medicine
Career Start Year 2005
Number of shared co-authors 17
Departments of Bioinformatics and Clinical Genomics, Illumina Inc.
Career Start Year 2005
Number of shared co-authors 1
David Geffen School of Medicine, University of California at Los Angeles
Career Start Year 2004
Number of shared co-authors 5
Cystic Fibrosis Foundation
Career Start Year 2003
Number of shared co-authors 36
Spanish National Cancer Research Centre (CNIO)
Career Start Year 2003
Number of shared co-authors 14
CRUK Cambridge Institute, University of Cambridge
Career Start Year 2003
Number of shared co-authors 6
Lewis-Sigler Institute for Integrative Genomics, Princeton University
Career Start Year 2001
Number of shared co-authors 15
The University of Texas Health Science Center at San Antonio
Career Start Year 2001
Number of shared co-authors 10
Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center
Career Start Year 2000
Number of shared co-authors 18
University Medical Centre Mannheim, University of Heidelberg
Career Start Year 2000
Number of shared co-authors 39
Schroeder Arthritis Institute
Career Start Year 1998
Number of shared co-authors 13
University of California San Diego
Career Start Year 1996
Number of shared co-authors 38
Columbia University
Career Start Year 1995
Number of shared co-authors 33
University of California San Diego
Career Start Year 1992
Number of shared co-authors 55
Harvard T. H. Chan School of Public Health
Career Start Year 1989
Number of shared co-authors 18
University of California San Diego
Career Start Year 1988
Number of shared co-authors 47
The College of New Jersey
Career Start Year 1988
Number of shared co-authors 7
Yale University School of Medicine
Career Start Year 1984
Number of shared co-authors 5

Collaborators

University of California
Co-authored papers 15
Genomics Institute, University of California Santa Cruz
Co-authored papers 14
Oregon Health & Science University
Co-authored papers 14
Duke University School of Medicine
Co-authored papers 13
Icahn School of Medicine
Co-authored papers 11
Columbia University Irving Medical Center
Co-authored papers 11
Harvard Medical School
Co-authored papers 11
University of California, Santa Cruz Genomics Institute
Co-authored papers 11
University of California san francisco
Co-authored papers 11
University of California los angeles
Co-authored papers 10
Rogel Cancer Center, University of Michigan ann arbor
Co-authored papers 10
University of California San Francisco
Co-authored papers 10
UCSF Medical Center-Mount Zion
Co-authored papers 10
Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill
Co-authored papers 10
University of California los angeles
Co-authored papers 10
Knight Cancer Institute, Oregon Health and Sciences University
Co-authored papers 9
University of California San Francisco
Co-authored papers 9
Dana-Farber Cancer Institute
Co-authored papers 9
Van Andel Institute
Co-authored papers 9
University of British Columbia
Co-authored papers 9
OHSU Knight Cancer Institute, Oregon Health & Science University
Co-authored papers 9
David Geffen School of Medicine, University of California los angeles
Co-authored papers 9
Bakar Computational Health Sciences Institute, University of California san francisco
Co-authored papers 8
The University of Texas MD Anderson Cancer Center
Co-authored papers 8
University of California San Diego
Co-authored papers 8
University of Adelaide
Co-authored papers 8
University of California
Co-authored papers 8
Buck Institute for Research on Aging
Co-authored papers 8
IBM T.J. Watson Research Center
Co-authored papers 8
University of California San Francisco
Co-authored papers 8